KCT0005454
Recruiting
未知
Effect of perioperative fixed-dose dual bronchodilator therapy on post-operative pulmonary function among mild- to -moderate COPD patients undergoing lung cancer surgery
ConditionsDiseases of th respiratory system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of th respiratory system
- Sponsor
- Samsung Medical Center
- Enrollment
- 204
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects of men or female over 40 years of age who are scheduled for curative pulmonary lobectomy due to confirmation (or high suspicion) of non\-small cell lung cancer (NSCLC)
- •Subjects waiting at least 14 days for scheduled pulmonary lobectomy
- •Subjects who are newly diagnosed with COPD\* or who have not used any bronchodilators within the past 3 months, even if they have previously been diagnosed with COPD
- •COPD : Post\-bronchodilator (Post\-BD) FEV1/FVC \<0\.7 and Post\-BD FEV1 \=70 %predicted (%pred)
- •Subjects with dyspnea of 0 or 1 grade measured by modified Medical Research Council (mMRC)
Exclusion Criteria
- •Pregnancy: subjects of women who are pregnant, lactating, planning on becoming pregnant during the clinical trial, or of child bearing potential not using contraception methods
- •COPD treatment/acute exacerbation: subjects who have been treated with COPD within the past 3 months or have experienced acute exacerbation of COPD within the past 1 month (Acute exacerbation of COPD is defined as the cases requiring antibiotics, oral corticosteroids, emergency treatment, or hospitalization due to at least one symptom from increased breathlessness, sputum volume, or sputum purulence)
- •Other pulmonary diseases: subjects who are physician\-diagnosed with asthma or Idiopathic Pulmonary Fibrosis (IPF)
- •Lung cancer treatment: subjects who have been received neo\-adjuvant treatment for lung cancer (chemotherapy, radiotherapy, or concurrent chemo\-radiotherapy)
- •Other diseases/abnormalities: subjects diagnosed with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities including medical condition corresponding to ‘warnings and precautions’ (such as coronary artery disease, acute myocardial infarction, cardiac arrhythmia, hypertension, convulsive disorders, thyrotoxicosis, hypokalemia, diabetes, narrow\-angle glaucoma, urinary retention, prostatic hyperplasia, bladderneck obstruction etc.) that are uncontrolled and/or with cancer within 5 years (Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.)
- •Abnormal and clinically significant 12\-Lead Eletrocardiogram (ECG): subjects with abnormal and clinically significant ECG findings (Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during
- •the study.)
- •Contraindications: subjects with a history of allergy or hypersensitivity to any Long\-Acting Muscarinic Antagonist (LAMA), Long\-Acting Beta\-Agonist (LABA), lactose/milk protein, stearic magnesium, with generic problems including galactose intolerance, Lapp lactose deficiency, or glucosegalactose malabsorption, or with contraindication of inhaled anticholinergiccontaining drugs
- •Mobility: subjects who are not able to walk independently without mobility assistance or other people
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer SurgeryChronic Obstructive Pulmonary DiseaseNon Small Cell Lung CancerNCT04536675Samsung Medical Center204
Completed
Not Applicable
Effect of mono or dual broncholdilator therapy on daily step count and six minutes walking distance in COPD patients.COPDJPRN-UMIN000013616Matsusaka Municipal Hospital Respiratory center35
Recruiting
Phase 3
Evaluation of the effect of comparing bronchodilators with corticosteroids and bronchodilators in children with bronchiolitisIRCT20220225054120N1Ilam University of Medical Sciences60
Active, not recruiting
Not Applicable
Comparison of standard and novel, double-active medications used to expand bronchi in diagnostic test in patients suffering from chronic lung disease (chronic obstructive pulmonary disease COPD and asthma).COPD (chronic obstructive pulmonary disease)Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2014-002667-15-ATMedizinische Universität Innsbruck, Innere Medizin VI
Recruiting
Not Applicable
The effect of inhaled bronchodilators on surgery for lung cancer surgery in patients with chronic obstructive lung disease; multicenter studyPrimary lung cancerJPRN-UMIN000025587Osaka University100